MK-4830

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Colorectal CancerSmall Cell Lung CancerEsophageal Squamous Cell CarcinomaCarcinoma, Renal Cell

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

1

Stivarga

Bayer

Phase 3

392

Adrucil

EElorac, Inc.

Phase 3

863

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

584

Acetylsalicylic Acid

Bayer

Phase 3

65

XL092

Roche

Phase 3

16

TAS 102

Taiho Oncology, Inc.

Phase 3

87

5-Fu

TToray Industries, Inc

Phase 3

48

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

29

Intravenous Methylene Blue

CChinese University of Hong Kong

Phase 3

110

MK-4830

Merck & Co.

Phase 2

1Show 38 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung3 trials

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Preclinical·NCT04165070·450 enrolled

KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Naïve Patients With PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Completed·Merck & Co.·Phase 2·NCT04165083·100 enrolled

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Completed·Merck & Co.·Phase 2·NCT04165096·128 enrolled

Small Cell Lung Cancer2 trials

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Recruiting·Merck & Co.·Phase 1/2·NCT04938817·110 enrolled

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Completed·Merck & Co.·Phase 2·NCT04924101·122 enrolled

Esophageal Cancer1 trial

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Completed·Merck & Co.·Phase 1/2·NCT05342636·90 enrolled

Advanced Solid Tumors1 trial

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Completed·Merck & Co.·Phase 1·NCT03564691·470 enrolled

Ovarian Cancer1 trial

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Completed·Merck & Co.·Phase 2·NCT05446870·160 enrolled

4 more indications

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting·Merck & Co.·Preclinical·NCT05319730·230 enrolled

Carcinoma, Renal Cell1 trial

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants

Completed·Merck & Co.·Preclinical·NCT04626518·263 enrolled

Melanoma1 trial

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C

Completed·Merck & Co.·Preclinical·NCT04303169·146 enrolled

Colorectal Cancer1 trial

A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

Active, not recruiting·Merck & Co.·Phase 2·NCT04895722·302 enrolled

Details

Drug Info

Related News